2care4 Generics ApS

CVR36960566
Selskabsregnskab

Nøgletal

Opdateret 23. apr. 2025
Afkastningsgrad
17 %
Egenkapitalforrentning
21,8 %
Likviditetsgrad
211,6 %
Soliditetsgrad
60,7 %

Resultat

Regnskabsperiode
Åbn PDF
Bruttoresultat
58.190.000
Driftsresultat
22.056.000
Finansielle indtægter
1.567.000
Finansielle omkostninger
1.618.000
Skat af årets resultat
4.812.000
Årets resultat
17.193.000

Medarbejdere

Regnskabsperiode
Åbn PDF
Gns. ansatte
28
Personaleomkostninger
30.346.000 kr.

Balance

Regnskabsperiode
Åbn PDF
Likvider
2.125.000
Kortfristede aktiver
86.496.000
Langfristede aktiver
43.242.000
Aktiver i alt
129.738.000
Egenkapital
78.737.000
Forpligtelser i alt
51.001.000
Kortfristede forpligtelser
40.878.000

Arbejdskapital

Regnskabsperiode
Åbn PDF
Varebeholdninger
55.748.000
Tilgodehavender fra salg og tjenesteydelser
21.121.000
Andre kortfristede tilgodehavender
1.253.000
Leverandørgæld
8.387.000

Kapital og udbytte

Regnskabsperiode
Åbn PDF
Selskabskapital
50.000
Overført resultat
46.892.000
Foreslået udbytte
0

Investeringer og aktiver

Regnskabsperiode
Åbn PDF
Langfristede investeringer og tilgodehavender
121.000
Materielle anlægsaktiver
348.000

Højdepunkter fra årsrapporten

Officiel årsrapport · 2024Åbn officiel rapport

Forretning og udvikling

Hovedaktiviteter

The Main activity of the company is to develop, import, produce and export generic pharmaceutical products.

Udvikling i aktiviteter og økonomiske forhold

The income statement of the Company for 2024 shows a profit of DKKm 17,2, and at 31 December 2024 the balance sheet of the Company shows a positive equity of DKKm 78,7.

Forventet udvikling

For the financial year 2025 the company expects slightly increased activity, and a net profit level in line with 2024 Research and development The development of the company includes implemented measures that within a few years in expected to generate increased revenue for the company. External environment The energy consumption and general environmental footprint from the 2care4 Generics activities are very limited and has limited impact on the surrounding environment. Since the medical products are purchased as commodities, the Company has little opportunity to assess and evaluate impacts on the environment in the supply chain. This given that there is no contact with the original producer as such and, therefore, the Company has no influence on the production phase at all.In our opinion…

Resultat sammenholdt med tidligere forventet udvikling

The Generics business has performed below expectations in 2024 driven by supply constraint on several key product lines.

Risici og væsentlige forhold

Usikkerhed ved indregning eller måling

There has been no uncertainty regarding recognition and measurement in the Annual Report.

Væsentlige begivenheder efter regnskabsperioden

No events materially affecting the assessment of the Annual Report have occurred after the balance sheet date.

Forpligtelser og sikkerhedsstillelser

Eventualforpligtelser

Rental and lease obligations The following assets have been placed as security for rent obligations for a period of 6 months. 312000 286000 Other contingent liabilities The group companies are jointly and severally liable for tax on the jointly taxed incomes etc of the Group. The total amount of corporation tax payable is disclosed in the Annual Report of 2care4 Group ApS, which is the management company of the joint taxation purposes. Moreover, the group companies are jointly and severally liable for Danish withholding taxes by way of dividend tax, tax on royalty payments and tax on unearned income. Any subsequent adjustments of corporation taxes and withholding taxes may increase the Company's liability.

Se op til 9 års regnskabshistorik ved at oprette en gratis bruger

Opret gratis bruger